Tyra Biosciences Reports Q3 GAAP EPS Miss of $0.07
Tyra Biosciences (TYRA) reported third-quarter financial results, revealing a GAAP earnings per share (EPS) of -$0.74. This figure missed analyst expectations by $0.07. Despite the earnings miss, the company maintains a strong liquidity position, reporting $700.5 million in cash, cash equivalents, and marketable securities as of September 30, 2026. Additionally, the company highlighted clinical progress regarding its initial SURF302 results for oral treatments.
Tickers: $TYRA
Topics: cash_position clinical_trial_results earnings_report